Royalty Pharma plc - Ordinary Shares - Class A Aktie News

NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an undisclosed third party for up to $315 million.

NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa.

SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa.

Royalty Pharma plc (RPRX) Presents at Evercore 8th Annual Healthcare Conference Transcript

Royalty Pharma plc (RPRX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December:

Royalty Pharma is reiterated as a Buy, supported by strong Q3 results, raised guidance, and disciplined capital deployment. The company trades at a notable discount to biopharma peers despite robust FCF, portfolio growth, and a diversified royalty-based business model. Platform model delivering diversified biopharma exposure, buybacks ongoing, and new deals to be priced in. Our buy is then conf...

Royalty Pharma plc ( RPRX ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants George Grofik - Senior VP and Head of Investor Relations & Communications Pablo Legorreta - Founder, Chairman of the Board & CEO Marshall Urist - Executive Vice President of Research & Investments Christopher Hite - Vice Chairman & Executive VP Terrance Coyne - Executive VP & CFO Conference Call ...